'Week 48' diaporamas de présentation

PROFILE - Trial Design

484 views • 36 slides

MONOTERAPIA CON DARUNAVIR/RITONAVIR

754 views • 35 slides

PROFILE - Trial Design

354 views • 35 slides

Key Research From IDSA 2007: The 45th Annual Meeting of the Infectious Diseases Society of America

Faculty Eric Daar, M.D. Key Research From IDSA 2007: The 45th Annual Meeting of the Infectious Diseases Society of America. San Diego, California | October 4-7, 2007. This activity is supported by an educational grant from. IDSA 2007: Faculty for This Activity. Eric Daar, M.D.

421 views • 33 slides

Thinking of Now and Tomorrow: Emerging Treatment Paradigms

Thinking of Now and Tomorrow: Emerging Treatment Paradigms. Pedro Cahn. Disclosures. Advisory boards : Merck, ViiV Healthcare Research funds : Abbvie , Merck, Richmond, ViiV Healthcare Speaker at educational activities : Abbvie , Gilead, Merck, ViiV Healthcare.

506 views • 32 slides

392 views • 29 slides

Investigator Meeting 2018

525 views • 23 slides

Encore1 study design

A daily dose of 400 mg efavirenz (EFV) is non-inferior to the standard 600 mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo controlled, non-inferiority trial Rebekah Puls for the ENCORE1 Study Group.

298 views • 19 slides

Track B: rapporteur highlights

Track B: rapporteur highlights. Laura Waters Mortimer Market Centre, CNWL, London, UK. @ drlaurajwaters. Share your thoughts on this presentation with #IAS2019. T eam B!. James McMahon. Colleen Kelley. Luis Mosqeueda. Sexually transmitted infections & PrEP.

191 views • 19 slides

XVIII International AIDS Conference ? Vienna, Austria ?18-23 July 2010

277 views • 17 slides

Background

Switching to Bictegravir / Emtricitabine / Tenofovir Alafenamide (B/F/TAF) in Adults Aged ? 65 Years: Week 24 Results from a Phase 3b, Open-Label Trial (GS-US-380-4449).

175 views • 17 slides

ING112276 Study Design

405 views • 16 slides

520 views • 16 slides

JR Arribas 1 , AL Pozniak 2 , JE Gallant 3 ,E DeJesus 4 , R Campo 5 ,

346 views • 15 slides

JR Arribas 1 , AL Pozniak 2 , JE Gallant 3 ,E DeJesus 4 , R Campo 5 ,

241 views • 15 slides

a ?10% non-inferiority margin for individual studies.

527 views • 13 slides

Comparison of INSTI vs PI

130 views • 13 slides

Le armi terapeutiche per il trattamento della Fibrosi Cistica: nuove acquisizioni

301 views • 10 slides

ACTIONS: Ashley French

ACTIONS: Ashley French . Update of lab layout and module assembly. B-162- R-011 . The rear wall has been repainted. Floor is being prepared and painted today (15/11/10 ) Wood will be placed in the side wall panels to cover the wire mesh on the 2 side walls then painted white.

187 views • 8 slides

Comparison of RTV vs Cobi

153 views • 7 slides